[Multicentric clinical trial of a combination of 35 micrograms of ethinylestradiol and 2 mg of cyproterone acetate].
The authors report the results of an open multicentric study of 136 women treated by a combination of 35 micrograms ethinylestradiol and 2 mg cyproterone acetate for cutaneous manifestation of hyperandrogenism. No pregnancy occurred during the treatment of 12 months. Comparison between the last treated and non treated cycle showed a significant difference (p less than 0.001) in the severity of acne lesions regardless of their sites. General and gynaecological tolerance were excellent.
Audebert
A
A
Emperaire
J C
JC
Gauthier
A
A
Hallonet
P
P
Hedon
B
B
Lopes
P
P
Quereux
C
C
Roulier
R
R
D000152:Acne Vulgaris / Q000453:epidemiology / Q000209:etiology; D000293:Adolescent; D000328:Adult; D000726:Androgen Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D001941:Breast Diseases / Q000453:epidemiology / Q000209:etiology; D003534:Cyproterone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017373:Cyproterone Acetate; D004359:Drug Therapy, Combination; D004997:Ethinyl Estradiol / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D010146:Pain / Q000453:epidemiology / Q000209:etiology; D014592:Uterine Hemorrhage / Q000453:epidemiology / Q000209:etiology; D014770:Virilism / Q000150:complications / Q000188:drug therapy*
D000726:Androgen Antagonists; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; D003534:Cyproterone
Etude clinique multicentrique d'une association de 35 micrograms d'éthinylestradiol et de 2 mg d'acétate de cyprotérone.